• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

FDA Clears AI-Powered Software for Thyroid Ultrasound

News
Article

Providing automated TI-RADS classifications and worksheets, the new AI-enabled software may facilitate improved efficiency with thyroid ultrasound exams.

The Food and Drug Administration (FDA) has granted 510(k) clearance for new AI-powered software geared toward thyroid ultrasound exams.

See-Mode Technologies, the developer of the software, said the software may help standardize assessment of thyroid ultrasound exams through automated TI-RADS classification of thyroid nodules. The company noted that results from a multi-reader, multi-case study demonstrated enhanced localization and characterization of thyroid nodules with adjunctive use of the AI software.

FDA Clears AI-Powered Software for Thyroid Ultrasound

The newly FDA-cleared AI software from See-Mode Technologies for thyroid ultrasound exams reportedly provides automated TI-RADS classification of thyroid nodules. (Image courtesy of Adobe Stock.)

Facilitating workflow efficiency, the software also generates automated worksheets and reportedly streamlines reporting on follow-up thyroid studies, according to See-Mode Technologies.

“By bringing AI into routine clinical practice, we aim to reduce the reporting time and inter-operator variability that exists in thyroid ultrasound,” noted Milad Mohammadzadeh, a co-founder of See-Mode Technologies.

The company added that existing CPT codes for adjunctive AI interpretation of thyroid ultrasound may be applied for use of the See-Mode Technologies software.

Recent Videos
Radiology Study Finds Increasing Rates of Non-Physician Practitioner Image Interpretation in Office Settings
Addressing the Early Impact of National Breast Density Notification for Mammography Reports
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Nina Kottler, MD, MS
The Executive Order on AI: Promising Development for Radiology or ‘HIPAA for AI’?
Expediting the Management of Incidental Pulmonary Emboli on CT
Radiology Challenges with Breast Cancer Screening in Women with Breast Implants
Related Content
© 2024 MJH Life Sciences

All rights reserved.